Vipul Organics has commenced commercial production at its new greenfield manufacturing facility located in Sayakha, Gujarat. The company marked the occasion with a formal Muhurat ceremony on August 20, 2026. As part of this operational development, pigment production that was previously undertaken at the company's Tarapur facility in Maharashtra has been moved to the new Sayakha location as part of a broader footprint-rationalisation exercise.

Production shift to Sayakha

The transition marks a consolidation of Vipul Organics' pigment manufacturing operations, with the Sayakha facility now taking over the production activities that were earlier based at Tarapur. The commencement of production at the new facility represents a significant operational milestone for the company, strengthening its pigment manufacturing capacities with infrastructure designed to progressively scale up in line with market demand.

Facility details and strategic positioning

The Sayakha facility is set up on an industrial plot of 24,633.11 square meters acquired from the Gujarat Industrial Development Corporation (GIDC), within Gujarat's Petroleum, Chemicals and Petrochemicals Investment Region (PCPIR). Strategically located on the Delhi-Mumbai Industrial Corridor, close to the proposed Dedicated Freight Corridor and adjacent to Dahej Port, the facility is positioned to strengthen the company's reach across both domestic and export markets.

The site is being developed as a consolidated manufacturing base. Alongside pigment powder, it hosts the membrane manufacturing operations of the company's unit, AdiMem Technologies, which commenced commercial sales of Reverse Osmosis (RO) and Ultrafiltration (UF) membranes earlier this year.

Mr. Vipul P. Shah, Managing Director, stated that the facility is built to expand pigment powder capacity and bring membrane and solvent dyes capabilities under one roof. He noted that as production stabilises over the coming quarters, Sayakha is expected to be a meaningful contributor to capacity and revenue diversification.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE834D01018/ba76d75f-442d-4998-a053-189f2260d5ed.pdf

Vipul Organics Limited reported a significant improvement in profitability for the first quarter of FY27, with consolidated net profit after tax (PAT) rising 99.75% year-on-year to ₹252.46 lakh. The specialty chemicals company posted total revenues of ₹5,217.52 lakh, marking a 38.44% increase from the ₹3,768.81 lakh recorded in Q1FY26.

Profit before tax (PBT) expanded sharply by 113% to ₹344.62 lakh on a standalone basis, outpacing the revenue growth and indicating improved operational efficiency. Earnings per share (EPS) grew 54.65% to ₹1.33 from ₹0.86 in the corresponding period last year on a consolidated basis.

Quarterly Performance

On a quarter-on-quarter basis, revenues remained relatively stable, declining marginally by 0.85% from ₹5,262.38 lakh in Q4FY26. However, profitability metrics showed consistent upward momentum. PBT rose 14.53% to ₹344.47 lakh, while PAT increased 27.93% to ₹252.46 lakh compared to the previous quarter.

The unaudited financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2026. Statutory auditors carried out a limited review of the standalone and consolidated financial results.

What the Numbers Show

The divergence between revenue growth and profit expansion highlights strong operating leverage. While revenues grew by 38.44%, profit before tax more than doubled with a 113% increase. This suggests that cost optimization initiatives are yielding immediate results, allowing a larger portion of incremental revenue to flow through to the bottom line. The company’s management noted that these efforts are beginning to translate into margin expansion.

Management Outlook

Vipul P. Shah, Managing Director, attributed the results to the continued strength of core businesses and progress in diversification. He stated that the current capital expenditure cycle is now complete, positioning the company for sustained growth. Additionally, the membrane division remains on track to add a new visible revenue stream in the coming quarters. The company is also finalizing its internal multi-decadal roadmap, Vision 2035, which will be shared with shareholders in due course.